Fulgent Total Current Liabilities vs Inventory Analysis

FLGT Stock

USD 21.39 0.25 1.18%

Fulgent Genetics financial indicator trend analysis is much more than just examining Fulgent Genetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulgent Genetics is a good investment. Please check the relationship between Fulgent Genetics Total Current Liabilities and its Inventory accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Total Current Liabilities vs Inventory

Total Current Liabilities vs Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulgent Genetics Total Current Liabilities account and Inventory. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Fulgent Genetics' Total Current Liabilities and Inventory is 0.9. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Inventory in the same time period over historical financial statements of Fulgent Genetics, assuming nothing else is changed. The correlation between historical values of Fulgent Genetics' Total Current Liabilities and Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Fulgent Genetics are associated (or correlated) with its Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory has no effect on the direction of Total Current Liabilities i.e., Fulgent Genetics' Total Current Liabilities and Inventory go up and down completely randomly.

Correlation Coefficient

0.9

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Fulgent Genetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Fulgent Genetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Inventory

Most indicators from Fulgent Genetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulgent Genetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.At this time, Fulgent Genetics' Discontinued Operations is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 93.4 M in 2024, whereas Tax Provision is likely to drop slightly above 2.5 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	777.1M	366.9M	96.6M	179.1M
Total Revenue	992.6M	619.0M	289.2M	266.7M

Gross Profit Total Revenue

Fulgent Genetics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Common Stock Total Equity	Common Stock	Other Liab
Total Assets		0.92	0.85	1.0	0.99	0.98	-0.87	0.98	0.85	0.87	0.82	-0.15	0.43	0.79	0.66	0.93	0.66	0.51	0.81	0.96	0.97	0.83	0.96	-0.59	-0.59	0.81
Other Current Liab	0.92		0.93	0.91	0.9	0.9	-0.78	0.85	0.94	0.81	0.74	-0.33	0.24	0.87	0.8	0.86	0.8	0.36	0.7	0.98	0.87	0.92	0.88	-0.58	-0.58	0.72
Total Current Liabilities	0.85	0.93		0.84	0.83	0.76	-0.84	0.78	1.0	0.91	0.48	-0.3	0.48	0.83	0.91	0.88	0.9	0.07	0.83	0.89	0.72	0.91	0.72	-0.56	-0.56	0.47
Total Stockholder Equity	1.0	0.91	0.84		0.99	0.98	-0.87	0.99	0.84	0.86	0.81	-0.15	0.43	0.79	0.65	0.93	0.64	0.52	0.82	0.95	0.97	0.83	0.96	-0.59	-0.59	0.81
Net Tangible Assets	0.99	0.9	0.83	0.99		0.98	-0.91	0.97	0.82	0.88	0.81	-0.04	0.47	0.72	0.68	0.92	0.68	0.48	0.84	0.96	0.96	0.77	0.96	-0.6	-0.6	0.79
Property Plant And Equipment Net	0.98	0.9	0.76	0.98	0.98		-0.79	0.96	0.77	0.77	0.91	-0.14	0.27	0.76	0.57	0.88	0.58	0.64	0.71	0.95	1.0	0.79	1.0	-0.59	-0.59	0.9
Net Debt	-0.87	-0.78	-0.84	-0.87	-0.91	-0.79		-0.83	-0.82	-0.98	-0.51	-0.19	-0.77	-0.53	-0.82	-0.87	-0.82	-0.09	-0.97	-0.85	-0.76	-0.63	-0.74	0.56	0.56	-0.46
Retained Earnings	0.98	0.85	0.78	0.99	0.97	0.96	-0.83		0.77	0.82	0.81	-0.17	0.42	0.78	0.55	0.88	0.55	0.58	0.78	0.89	0.96	0.79	0.95	-0.48	-0.48	0.83
Accounts Payable	0.85	0.94	1.0	0.84	0.82	0.77	-0.82	0.77		0.89	0.5	-0.32	0.43	0.85	0.9	0.89	0.9	0.1	0.81	0.89	0.73	0.92	0.73	-0.6	-0.6	0.49
Cash	0.87	0.81	0.91	0.86	0.88	0.77	-0.98	0.82	0.89		0.47	0.07	0.74	0.63	0.85	0.91	0.85	0.06	0.98	0.85	0.74	0.72	0.72	-0.57	-0.57	0.43
Non Current Assets Total	0.82	0.74	0.48	0.81	0.81	0.91	-0.51	0.81	0.5	0.47		-0.16	-0.08	0.64	0.26	0.65	0.27	0.86	0.37	0.8	0.93	0.62	0.94	-0.44	-0.44	0.99
Non Currrent Assets Other	-0.15	-0.33	-0.3	-0.15	-0.04	-0.14	-0.19	-0.17	-0.32	0.07	-0.16		0.45	-0.69	-0.02	-0.18	0.0	-0.27	0.15	-0.14	-0.17	-0.6	-0.17	0.13	0.13	-0.28
Other Assets	0.43	0.24	0.48	0.43	0.47	0.27	-0.77	0.42	0.43	0.74	-0.08	0.45		0.05	0.56	0.5	0.54	-0.36	0.84	0.33	0.24	0.15	0.21	-0.24	-0.24	-0.11
Cash And Short Term Investments	0.79	0.87	0.83	0.79	0.72	0.76	-0.53	0.78	0.85	0.63	0.64	-0.69	0.05		0.55	0.81	0.55	0.46	0.53	0.78	0.77	0.99	0.77	-0.53	-0.53	0.7
Net Receivables	0.66	0.8	0.91	0.65	0.68	0.57	-0.82	0.55	0.9	0.85	0.26	-0.02	0.56	0.55		0.71	1.0	-0.24	0.79	0.78	0.5	0.68	0.51	-0.5	-0.5	0.19
Common Stock Shares Outstanding	0.93	0.86	0.88	0.93	0.92	0.88	-0.87	0.88	0.89	0.91	0.65	-0.18	0.5	0.81	0.71		0.7	0.34	0.88	0.88	0.86	0.85	0.85	-0.78	-0.78	0.65
Inventory	0.66	0.8	0.9	0.64	0.68	0.58	-0.82	0.55	0.9	0.85	0.27	0.0	0.54	0.55	1.0	0.7		-0.23	0.78	0.79	0.5	0.68	0.52	-0.48	-0.48	0.2
Other Current Assets	0.51	0.36	0.07	0.52	0.48	0.64	-0.09	0.58	0.1	0.06	0.86	-0.27	-0.36	0.46	-0.24	0.34	-0.23		0.0	0.41	0.7	0.36	0.7	-0.22	-0.22	0.9
Other Stockholder Equity	0.81	0.7	0.83	0.82	0.84	0.71	-0.97	0.78	0.81	0.98	0.37	0.15	0.84	0.53	0.79	0.88	0.78	0.0		0.76	0.67	0.62	0.65	-0.6	-0.6	0.35
Total Liab	0.96	0.98	0.89	0.95	0.96	0.95	-0.85	0.89	0.89	0.85	0.8	-0.14	0.33	0.78	0.78	0.88	0.79	0.41	0.76		0.92	0.84	0.93	-0.59	-0.59	0.76
Property Plant And Equipment Gross	0.97	0.87	0.72	0.97	0.96	1.0	-0.76	0.96	0.73	0.74	0.93	-0.17	0.24	0.77	0.5	0.86	0.5	0.7	0.67	0.92		0.78	1.0	-0.56	-0.56	0.93
Total Current Assets	0.83	0.92	0.91	0.83	0.77	0.79	-0.63	0.79	0.92	0.72	0.62	-0.6	0.15	0.99	0.68	0.85	0.68	0.36	0.62	0.84	0.78		0.78	-0.57	-0.57	0.66
Property Plant Equipment	0.96	0.88	0.72	0.96	0.96	1.0	-0.74	0.95	0.73	0.72	0.94	-0.17	0.21	0.77	0.51	0.85	0.52	0.7	0.65	0.93	1.0	0.78		-0.57	-0.57	0.93
Common Stock Total Equity	-0.59	-0.58	-0.56	-0.59	-0.6	-0.59	0.56	-0.48	-0.6	-0.57	-0.44	0.13	-0.24	-0.53	-0.5	-0.78	-0.48	-0.22	-0.6	-0.59	-0.56	-0.57	-0.57		1.0	-0.41
Common Stock	-0.59	-0.58	-0.56	-0.59	-0.6	-0.59	0.56	-0.48	-0.6	-0.57	-0.44	0.13	-0.24	-0.53	-0.5	-0.78	-0.48	-0.22	-0.6	-0.59	-0.56	-0.57	-0.57	1.0		-0.41
Other Liab	0.81	0.72	0.47	0.81	0.79	0.9	-0.46	0.83	0.49	0.43	0.99	-0.28	-0.11	0.7	0.19	0.65	0.2	0.9	0.35	0.76	0.93	0.66	0.93	-0.41	-0.41

Click cells to compare fundamentals

Fulgent Genetics Account Relationship Matchups

Fulgent Genetics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	88.8M	700.5M	1.3B	1.4B	1.3B	1.3B
Other Current Liab	3.6M	62.7M	36.7M	58.4M	49.1M	51.6M
Total Current Liabilities	6.0M	131.1M	112.8M	116.2M	73.0M	49.4M
Total Stockholder Equity	82.8M	569.4M	1.2B	1.3B	1.1B	1.2B
Net Tangible Assets	82.8M	569.4M	1.2B	973.0M	1.1B	1.2B
Property Plant And Equipment Net	6.0M	40.2M	62.3M	81.4M	94.3M	99.0M
Net Debt	(9.3M)	(71.6M)	(164.9M)	(58.9M)	(82.6M)	(78.4M)
Retained Earnings	(63.4M)	150.9M	657.6M	801M	633.2M	664.8M
Accounts Payable	1.6M	26.5M	20.5M	23.1M	15.4M	10.3M
Cash	12.0M	87.4M	164.9M	79.5M	97.5M	50.9M
Non Current Assets Total	12.0M	84.7M	62.3M	480.4M	765.3M	803.5M
Non Currrent Assets Other	(36.8M)	(88.0M)	142.0M	(287.4M)	32.0M	33.6M
Other Assets	251K	44.5M	912.6M	26.6M	1.0	0.95
Cash And Short Term Investments	70.2M	431.9M	164.9M	852.9M	424.2M	227.7M
Net Receivables	6.6M	183.9M	138.9M	52.7M	57.4M	50.2M
Common Stock Shares Outstanding	18.7M	24.1M	31.2M	31.0M	29.8M	23.5M
Liabilities And Stockholders Equity	88.8M	700.5M	1.3B	1.4B	1.3B	1.3B
Inventory	277K	16.5M	12.2M	4.3M	5.8M	4.4M
Other Current Assets	277K	(16.5M)	(12.2M)	22.2M	26.2M	27.6M
Other Stockholder Equity	146.1M	418.1M	1.2B	477.4M	481.3M	332.8M
Total Liab	6.0M	131.1M	112.8M	116.2M	139.8M	146.8M
Property Plant And Equipment Gross	8.6M	41.0M	81.9M	124.6M	135.1M	141.9M
Total Current Assets	76.8M	615.7M	303.8M	905.6M	507.8M	280.8M
Accumulated Other Comprehensive Income	146K	438K	(759K)	(20.9M)	1.2M	1.3M
Property Plant Equipment	8.6M	40.2M	62.3M	98.9M	113.8M	119.4M
Retained Earnings Total Equity	(63.0M)	(63.4M)	150.9M	657.6M	756.2M	794.0M
Short Term Investments	58.3M	344.4M	770.7M	773.4M	326.7M	326.9M
Non Current Liabilities Total	2.3M	959K	7.5M	28.1M	66.8M	70.1M
Capital Surpluse	114.2M	146.1M	418.1M	501.9M	577.2M	606.1M
Long Term Investments	42.8M	132.5M	507.0M	339.0M	444.0M	466.2M
Non Current Liabilities Other	2.3M	959K	7.5M	28.1M	11.0M	6.8M
Net Invested Capital	82.8M	584.4M	1.2B	1.3B	1.1B	688.3M
Net Working Capital	33.4M	393.5M	961.6M	539.8M	434.8M	381.8M

Pair Trading with Fulgent Genetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fulgent Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fulgent Genetics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Fulgent Stock

0.69	VVOS	Vivos TherapeuticsInc	Pair Corr
0.68	FIGS	Figs Inc	Pair Corr
0.7	XAIR	Beyond Air Financial Report 27th of June 2024	Pair Corr

Moving against Fulgent Stock

0.65	NXL	Nexalin Technology	Pair Corr
0.52	IRIX	IRIDEX	Pair Corr

The ability to find closely correlated positions to Fulgent Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fulgent Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fulgent Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fulgent Genetics to buy it.

The correlation of Fulgent Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fulgent Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fulgent Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Fulgent Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Fulgent Genetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Fulgent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Fulgent Genetics Stock. Highlighted below are key reports to facilitate an investment decision about Fulgent Genetics Stock:

How To Invest In Fulgent

Details

Is Fulgent Stock a good investment?

Details

What is Fulgent Genetics' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Fulgent Stock analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Commodity Directory Find actively traded commodities issued by global exchanges
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Earnings Share

(5.56)

Revenue Per Share

9.635

Quarterly Revenue Growth

(0.03)

Return On Assets

(0.03)

The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fulgent Total Current Liabilities vs Inventory Analysis

Total Current Liabilities vs Inventory

Total Current Liabilities vs Inventory Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Inventory

Fulgent Genetics fundamental ratios Correlations

Fulgent Genetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fulgent Genetics fundamental ratios Accounts

Pair Trading with Fulgent Genetics

Moving together with Fulgent Stock

Moving against Fulgent Stock

Complementary Tools for Fulgent Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Current Liabilities
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant Equipment	+ 1.0	Property Plant And Equipment Net
Inventory	+ 1.0	Net Receivables
Property Plant Equipment	+ 1.0	Property Plant And Equipment Gross

Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.97	Net Debt
Net Debt	- 0.91	Net Tangible Assets
Common Stock Shares Outstanding	- 0.87	Net Debt
Net Debt	- 0.87	Total Stockholder Equity
Net Debt	- 0.87	Total Assets